MedTrace Logo

Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study

NCT02362880 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-04-14

No results posted yet for this study

Summary

The main purpose of the study is to assess safety of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

RADIATION

Florbetaben

single dose of Florbetaben followed by PET scan

Sponsors & Collaborators

  • Judit Pich Martínez

    lead OTHER

Principal Investigators

  • Raquel Sánchez · Hospital Clinic of Barcelona

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02362880 on ClinicalTrials.gov